ISPD cardiovascular and metabolic guidelines in adult peritoneal dialysis patients part II – management of various cardiovascular complications

Peritoneal Dialysis International

Volumn 35, Issue 4, 2015, Pages 388-396

  Wang, Angela Yee ^a   Brimble, K Scott ^b   Brunier, Gillian ^c   Holt, Stephen G ^d   Jha, Vivekanand ^e   Johnson, David W ^f,g   Kang, Shin Wook ^h   Kooman, Jeroen P ⁱ   Lambie, Mark ^j   McIntyre, Chris ^k   Mehrotra, Rajnish ^l   Pecoits Filho, Roberto ^m  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^h Yonsei University   (South Korea)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^j KEELE UNIVERSITY   (United Kingdom)

^k UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^l UNIVERSITY OF WASHINGTON   (United States)

^m PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

more..

Author keywords

Atrial fibrillation; Coronary artery disease; Heart failure; Left ventricular hypertrophy; Peripheral artery disease; Peritoneal dialysis; Stroke; Sudden cardiac death

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE; TROPONIN; WARFARIN;

ADULT; ANEMIA; ANGIOPLASTY; ANKLE BRACHIAL INDEX; ARTICLE; ATRIAL FIBRILLATION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; HYPERTENSION; INTERNATIONAL SOCIETY FOR PERITONEAL DIALYSIS GUIDELINE; META ANALYSIS (TOPIC); MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; HYPERTROPHY, LEFT VENTRICULAR; MALE; MEDICAL SOCIETY; PATHOLOGY; PROGNOSIS; STANDARDS; STROKE; SURVIVAL ANALYSIS;

ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; HEART FAILURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; PERITONEAL DIALYSIS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SOCIETIES, MEDICAL; STROKE; SURVIVAL ANALYSIS;

EID: 84938243240     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2014.00278     Document Type: Article

References (59)

1. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339:799-805.
2. Stack AG, Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis 2002; 40:1202-10.
3. Wang AY, Wang M, Woo J Lam CW, Lui SF, Li PK, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004; 15:2186-94.
4. Wang AY, Wang M, Lam CW, Chan IH, Lui SF, Sanderson JE. Heart failure in long-term peritoneal dialysis patients: a 4-year prospective analysis. Clin J Am Soc Nephrol 2011; 6:805-12.
5. Wang AY, Wang M, Lam CW, Chan IH, Lui SF, Sanderson JE. Heart failure with preserved or reduced ejection fraction in patients treated with peritoneal dialysis. Am J Kidney Dis 2013; 61:975-83.
6. Trespalacios FC, Taylor AJ, Agodoa LY, Bakris GL, Abbott KC. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 2003; 41:1267-77.
7. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 2012; 59(1 Suppl 1):A7, e1-420.
8. Wang AY, Lam CW, Chan IH, Wang M, Lui SF, Sanderson JE. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. Hypertension 2010; 56:210-6.
9. Wang HH, Hung SY, Sung JM, Hung KY, Wang JD. Risk of stroke in long-term dialysis patients compared with the general population. Am J Kidney Dis 2014; 63:604-11.
10. Liu JH, Lin HH, Yang YF, Liu YL, Kuo HL, Wang IK, et al. Subclinical peripheral artery disease in patients undergoing peritoneal dialysis: risk factors and outcome. Petit Dial Int 2009; 29:64-71.
11. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77:1098-106.
12. Genovesi S, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A, et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 2008; 51:255-62.
13. Wang AY, Wai-Kei Lam C. The diagnostic utility of cardiac biomarkers in dialysis patients. Semin Dial 2012; 25:388-96.
14. Melloni C, Alexander KP, Milford-Beland S, Newby LK, Szczech LA, Crusade Investigators, et al. Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease. Clin Cardiol 2008; 31:125-9.
15. Newby LK, Jesse RL, Babb JD, Christenson RH, De Fer TM, Diamond GA, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2012; 60:2427-63.
16. NACB Writing Group, Wu AH, Jaffe AS, Apple FS, Jesse RL, Francis GL, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 2007; 53:2086-96.
17. Garg R, Singh A, Khaja A, Martin A, Aggarwal K. How does volume status affect BNP and troponin levels as markers of cardiovascular status in peritoneal dialysis? Congest Heart Fail 2009; 15:240-4.
18. Gowdak LH, Arantes RL, de Paula FJ, Krieger EM, De Lima JJ. Underuse of American College of Cardiology/American Heart Association Guidelines in hemodialysis patients. Ren Fail 2007; 29(5):559-65.
19. Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Peripheral Vascular Disease, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2012; 60:434-80.
20. Friedman SE, Palac RT, Zlotnick DM, Chobanian MC, Costa SP. A call to action: variability in guidelines for cardiac evaluation before renal transplantation. Clin J Am Soc Nephrol 2011; 6:1185-91.
21. Sharma R, Pellerin D, Gaze DC, Gregson H, Streather CP, Collinson PO, et al. Dobutamine stress echocardiography and the resting but not exercise electrocardiograph predict severe coronary artery disease in renal transplant candidates. Nephrol Dial Transplant 2005; 20:2207-14.
22. Rabbat CG, Treleaven DJ, Russell JD, Ludwin D, Cook DJ. Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis. J Am Soc Nephrol 2003; 14:431-9.
23. Tomaszuk-Kazberuk A, Kozuch M, Malyszko J, Bachorzewska-Gajewska H, Dobrzycki S, Musial WJ. Pharmacologic treatment in dialysis patients hospitalized for cardiovascular reasons: do we follow the guidelines? Ren Fail 2013; 35(2):235-42.
24. Dempster DW, Rosenstock JL, Schwimmer JA, Panagopoulos G, DeVita MV, Michelis MF. Underutilization of aspirin in hemodialysis patients for primary and secondary prevention of cardiovascular disease. Clin Nephrol 2005; 64(5):371-7.
25. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013; 2:CD008834.
26. Wang AY, Wang M, Lam CW, Chan IH, Zhang Y, Sanderson JE. Left ventricular filling pressure by Doppler echocardiography in patients with end-stage renal disease. Hypertension 2008; 52:107-14.
27. Zannad F, Kessler M, Lehert P, Griinfeld JP, Thuilliez C, Leizorovicz A, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70:1318-24.
28. Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, et al. Cande-sartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study. Nephrol Dial Transplant 2006; 21:2507-12.
29. Cice G, Di Benedetto A, D'Isa S, D'Andrea A, Marcelli D, Gatti E, et al. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 2010; 56:1701-8.
30. Yang LY, Ge X, Wang YL, Ma KL, Liu H, Zhang XL, et al. Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: a metaanalysis. Am J Med Sci 2013; 345:1-9.
31. Cice G, Ferrara L, Di Benedetto A, Russo PE, Marinelli G, Pavese F, et al. Dilated cardiomyopathy in dialysis patients—beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001; 37:407-11.
32. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41:1438-44.
33. Ito Y, Mizuno M, Suzuki Y, Tamai H, Hiramatsu T, Nagoya Spiro Study Group, et al. Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol 2014; 25:1094-102.
34. Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 2014; 63:528-36.
35. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:227-76.
36. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:517-84.
37. Palmer SC, DI Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 156:445-59.
38. Furie KL, Goldstein LB, Albers GW, Khatri P, Neyens R, Turakhia MP, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012; 43:3442-53.
39. Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis 2007; 50(3):433-40.
40. Zimmerman, D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence, prevalence and outcome of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012; 27:3816-22.
41. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013; 34(27):2094-106.
42. Cove CL, Hylek EM. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc 2013; 2(5):e000136.
43. Tariq N, Adil MM, Saeed F, Chaudhry SA, Qureshi AI. Outcomes of thrombolytic treatment for acute ischemic stroke in dialysis-dependent patients in the United States. J Stroke Cerebrovasc Dis 2013; 22(8):e354-59.
44. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney Int 2013; 83:91-111.
45. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113: e463-654.
46. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary. A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006; 47:1239-312.
47. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33(Suppl 1):S1-75.
48. Frans FA, Bipat S, Reekers JA, Legemate DA, Koelemay MJ. Systematic review of exercise training or percutaneous transluminal angioplasty for intermittent claudication. Br J Surg 2012; 99:16-28.
49. Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev 2008; CD000990.
50. K/DOQI Workgroup et al. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1-153.
51. Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80:572-86.
52. Abbott KC, Trespalacios FC, Taylor AJ, Agodoa LY. Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol 2003; 4:1-10.
53. Genovesi S, Pogliani D, Faini A, Valsecchi MG, Riva A, Stefani F, et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005; 46:897-902.
54. Vazquez E, Sanchez-Perales C, Lozano C, Garcia-Cortes MJ, Borrego F, Guzman M, et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 2003; 92:868-71.
55. USRDS Annual Data Report. Cardiovascular special studies. [Available online at: http://www.usrds.org/2004/pdf/09_cardio_04.pdf ]
56. Pun PH, Lehrich RW, Smith SR, Middleton JP. Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol 2007; 2:491-500.
57. Tangri N, Shastri S, Tighiouart H, Beck GJ, Cheung AK, Eknoyan G, et al. B-blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO study. Am J Kidney Dis 2011; 58(6):939-45.
58. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML; MADIT-II Investigators. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 2004; 43(8):1459-65.
59. Herzog CA, Li S, Weinhandl ED, Strief JW, Collins AJ, Gilbertson DT. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005; 68(2):818-85.